3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
55
Neoplasm Metastasis
17
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasms
14
Pancreatic Neoplasms
11
Uveal Melanoma
10
Prostatic Neoplasms
10
Leukemia, Myeloid, Acute
9
Squamous Cell Carcinoma of Head and Neck
7
Sarcoma
7
Myelodysplastic Syndromes
7
Lymphoma
7
Lung Neoplasms
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Recurrence
5
Myeloproliferative Disorders
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Hematologic Neoplasms
5
Glioblastoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Interventions
Dexamethasone
2
vistusertib
1
ricolinostat
1
pomalidomide
1
irinotecan sucrosofate
1
idelalisib
1
daratumumab
1
bermekimab
1
atezolizumab
1
alovudine
1
TKM-080301
1
TIC10 compound
1
S-Adenosylmethionine
1
Prostatectomy
1
Pluvicto
1
MicroRNAs
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Ipilimumab
1
Ga(III)-DOTATOC
1
Fluorouracil
1
Cyclophosphamide
1
Blood Specimen Collection
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Disease
×
Ipilimumab
×
Clear all
NCT04855929
2024-11-08
ANV419-001
Anaveon AG
Phase 1
Completed
55 enrolled